Insider Selling: AnaptysBio, Inc. (NASDAQ:ANAB) Insider Sells $52,500.00 in Stock

AnaptysBio, Inc. (NASDAQ:ANAB) insider Paul F. Lizzul sold 1,500 shares of the business’s stock in a transaction dated Thursday, July 18th. The stock was sold at an average price of $35.00, for a total value of $52,500.00. Following the transaction, the insider now owns 11,618 shares of the company’s stock, valued at $406,630. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.

AnaptysBio Stock Performance

NASDAQ ANAB opened at $33.70 on Monday. The stock has a market capitalization of $920.68 million, a price-to-earnings ratio of -5.49 and a beta of -0.25. The stock’s 50 day moving average price is $25.51 and its two-hundred day moving average price is $24.06. AnaptysBio, Inc. has a 52 week low of $13.36 and a 52 week high of $37.28.

AnaptysBio (NASDAQ:ANAB) last released its earnings results on Thursday, May 9th. The biotechnology company reported ($1.64) EPS for the quarter, missing the consensus estimate of ($1.54) by ($0.10). The firm had revenue of $7.18 million during the quarter, compared to the consensus estimate of $4.55 million. AnaptysBio had a negative net margin of 711.17% and a negative return on equity of 161.40%. On average, equities research analysts forecast that AnaptysBio, Inc. will post -6.04 EPS for the current year.

Institutional Investors Weigh In On AnaptysBio

Institutional investors have recently bought and sold shares of the company. Allspring Global Investments Holdings LLC bought a new stake in AnaptysBio in the 1st quarter valued at approximately $38,000. China Universal Asset Management Co. Ltd. raised its stake in shares of AnaptysBio by 350.4% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 3,072 shares of the biotechnology company’s stock worth $66,000 after purchasing an additional 2,390 shares in the last quarter. Quest Partners LLC bought a new stake in shares of AnaptysBio during the 4th quarter worth approximately $119,000. SG Americas Securities LLC bought a new stake in shares of AnaptysBio during the 4th quarter worth approximately $126,000. Finally, Virtu Financial LLC bought a new stake in shares of AnaptysBio during the 1st quarter worth approximately $222,000.

Analyst Ratings Changes

Several equities analysts have recently issued reports on ANAB shares. Wells Fargo & Company started coverage on AnaptysBio in a research report on Thursday, April 11th. They set an “overweight” rating and a $56.00 target price for the company. Leerink Partnrs reiterated an “outperform” rating on shares of AnaptysBio in a research report on Tuesday, April 16th. SVB Leerink started coverage on AnaptysBio in a research report on Tuesday, April 16th. They issued an “outperform” rating and a $47.00 price objective for the company. JPMorgan Chase & Co. upgraded AnaptysBio from a “neutral” rating to an “overweight” rating and boosted their price objective for the company from $29.00 to $69.00 in a research report on Friday. Finally, Wedbush reiterated an “outperform” rating and issued a $34.00 price objective on shares of AnaptysBio in a research report on Friday, May 10th. One research analyst has rated the stock with a sell rating, one has given a hold rating and eight have issued a buy rating to the stock. According to MarketBeat.com, AnaptysBio currently has an average rating of “Moderate Buy” and a consensus price target of $51.50.

About AnaptysBio

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.